Literature DB >> 31820021

[AR-V7 as a predictive biomarker for prostate cancer-more than just prophecy].

C Bernemann1, L-M Krabbe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31820021     DOI： 10.1007/s00120-019-01086-8

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  12 in total

Review 1.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

2.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Mary Nakazawa; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

3.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

4.  Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods.

Authors:  Christof Bernemann; Julie Steinestel; Verena Humberg; Martin Bögemann; Andres Jan Schrader; Jochen K Lennerz
Journal:  BJU Int       Date:  2018-02-14       Impact factor: 5.588

5.  Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?

Authors:  Julie Steinestel; Christof Bernemann; Andres J Schrader; Jochen K Lennerz
Journal:  Eur Urol       Date:  2017-07-05       Impact factor: 20.096

6.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Authors:  Ronald de Wit; Johann de Bono; Cora N Sternberg; Karim Fizazi; Bertrand Tombal; Christian Wülfing; Gero Kramer; Jean-Christophe Eymard; Aristotelis Bamias; Joan Carles; Roberto Iacovelli; Bohuslav Melichar; Ásgerður Sverrisdóttir; Christine Theodore; Susan Feyerabend; Carole Helissey; Ayse Ozatilgan; Christine Geffriaud-Ricouard; Daniel Castellano
Journal:  N Engl J Med       Date:  2019-09-30       Impact factor: 91.245

7.  Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Authors:  Wendy Onstenk; Anieta M Sieuwerts; Jaco Kraan; Mai Van; Annemieke J M Nieuweboer; Ron H J Mathijssen; Paul Hamberg; Hielke J Meulenbeld; Bram De Laere; Luc Y Dirix; Robert J van Soest; Martijn P Lolkema; John W M Martens; Wytske M van Weerden; Guido W Jenster; John A Foekens; Ronald de Wit; Stefan Sleijfer
Journal:  Eur Urol       Date:  2015-07-15       Impact factor: 20.096

8.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Authors:  Andrew J Armstrong; Susan Halabi; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Patrick Healy; Monika Anand; Colin J Rothwell; Julia Rasmussen; Blair Thornburg; William R Berry; Rhonda S Wilder; Changxue Lu; Yan Chen; John L Silberstein; Gabor Kemeny; Giuseppe Galletti; Jason A Somarelli; Santosh Gupta; Simon G Gregory; Howard I Scher; Ryan Dittamore; Scott T Tagawa; Emmanuel S Antonarakis; Daniel J George
Journal:  J Clin Oncol       Date:  2019-03-13       Impact factor: 44.544

9.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

10.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.

Authors:  Adam Sharp; Ilsa Coleman; Wei Yuan; Cynthia Sprenger; David Dolling; Daniel Nava Rodrigues; Joshua W Russo; Ines Figueiredo; Claudia Bertan; George Seed; Ruth Riisnaes; Takuma Uo; Antje Neeb; Jonathan Welti; Colm Morrissey; Suzanne Carreira; Jun Luo; Peter S Nelson; Steven P Balk; Lawrence D True; Johann S de Bono; Stephen R Plymate
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.